BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

The last time I spoke about Praxis Precision Medicines, Inc. (NASDAQ:PRAX), it was in a Seeking Alpha article entitled "Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide." At ...

Praxis Precision Medicines Inc PRAX announced topline results from the PRAX-628 Phase 1 healthy volunteer study evaluating single ascending doses (SAD) and multiple ascending doses (MAD) of PRAX-628.

BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) ...

BRENTWOOD, Tenn. - (Business Wire) Praxis, a company specializing in centralized patient recruitment for clinical research studies, will provide patient recruitment services to a top 20 pharmaceutical ...

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Earnings call Praxis reported top-line results from its RADIANT study showing vimatrogene achieved a 56% median seizure reduction and 60% responder rate in refractory focal epilepsy patients, ...

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced its ...